Generalized anxiety disorder (GAD) is an anxiety disorder characterized by excessive, uncontrollable, and often irrational worry about events or activities. Worry often interferes with daily functioning. Individuals with GAD are often, but not necessarily, overly concerned about everyday matters such as health, finances, death, family, relationship concerns, or work difficulties."What Is Generalized Anxiety Disorder?", National Institute of Mental Health. Accessed 28 May 2008. Symptoms may include excessive worry, restlessness, trouble sleeping, exhaustion, irritability, sweating, and trembling.
Symptoms must be consistent and ongoing, persisting at least six months for a formal diagnosis. Individuals with GAD often have other disorders including other psychiatric disorders, substance use disorder, or obesity, and may have a history of trauma or family with GAD. Clinicians use screening tools such as the GAD-7 and GAD-2 questionnaires to determine if individuals may have GAD and warrant formal evaluation for the disorder. In addition, screening tools may enable clinicians to evaluate the severity of GAD symptoms.
Treatment includes types of psychotherapy and pharmacological intervention; combined therapy is generally considered most effective. Cognitive behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) are the first-line psychological and pharmacological treatments. In more severe, last-resort cases, benzodiazepines (BZs) may be used, as BZs are habit-forming and frequently abused. Pregabalin is an additional effective treatment for GAD; it has a low risk of dependence.European Medicines Agency. EPAR summary for the public (Lyrica/pregabalin) EMA/229012/2010.ClinCalc. Drug Usage Statistics, United States, 2013 - 2022. The potential effects of complementary and alternative medications (CAMs), exercise, therapeutic massage, and other interventions have been studied. Brain stimulation, LSD, and other novel therapeutic interventions are also under study.
Genetic and environmental factors both contribute to GAD. A hereditary component influenced by brain structure and neurotransmitter function interacts with life stressors such as parenting style and abusive relationships. Emerging evidence also links problematic digital media use to increased anxiety. GAD involves heightened amygdala and prefrontal cortex activity, reflecting an overactive threat-response system. It affects about 2–6% of adults worldwide, usually begins in adolescence or early adulthood, is more common in women, and often recurs throughout life. GAD was defined as a separate diagnosis in 1980, with changing criteria over time that have complicated research and treatment development.
Causes
Genetics, family, and environment
The relationship between genetics and anxiety disorders remains an active area of investigation. Although GAD is understood to have a hereditary basis, the precise mechanisms remain unclear. Researchers have identified several genetic loci of interest, but no single gene or set of genes has been definitively linked to the disorder. Genetic elements contribute to an individual's risk of developing GAD, to structural changes in the brain associated with anxiety, and to variability in treatment response. Genetics is typically considered alongside environmental exposures, such as adverse life experiences and chronic stress.
Evidence from family and twin studies supports a strong genetic component, showing that GAD occurs more frequently among first-degree relatives than in unrelated individuals. Funk and colleagues, in a June 2025 article in Psychological Medicine, reported that genetic factors accounted for continuity in GAD symptoms, while environmental factors drove symptom changes. Heritability at single assessments was 39–46%; when stability across ages 23–26 was modeled, heritability rose to ~60%, highlighting stronger genetic influence in persistent GAD. Summarizing twin and genome-wide association studies in a 2025 article in Psychiatric Clinics of North America, Weber and colleagues reported that overall genetic contribution to anxiety disorders, including GAD, ranges from 30 to 50%, with SNP‑based heritability between 5–30%. This suggests that common variants explain only part of the risk, while rare variants and epigenetic processes contribute substantially. Twin studies further suggest a genetic linkage between GAD and major depressive disorder (MDD), which may account for the high frequency of comorbidity—estimated at roughly 60%—between the two conditions.
Environmental influences have been examined in relation to parenting styles, with suggestions that parental modeling of anxious behaviors may contribute to risk. Individuals with GAD also appear to experience a greater number of minor stress-related events, and these cumulative stressors may be significant in the disorder's development. Social context has been shown to matter as well; research highlights associations between interpersonal difficulties and GAD, including findings that partner abuse in women is strongly linked to anxiety symptoms. Strained or abusive relationships therefore appear to be one environmental factor associated with the emergence of GAD.
Genetic studies have also explored the role of genes involved in brain structures such as the amygdala, as well as those affecting neurotransmitter systems and receptor activity. Among the genes studied, several have been linked to treatment response. For example, the Asp54Gly polymorphism of the pituitary adenylate cyclase-activating peptide, which is the product of the ADCYAP1 gene, has been associated with remission following venlafaxine treatment for GAD. Variants in the gene encoding serotonin receptor 2A, HTR2A, particularly the rs7997012 SNP G allele, have been implicated in reductions in anxiety symptoms after venlafaxine therapy. Finally, interactions between serotonin transporter gene SLC6A4 and HTR2A polymorphisms have also been shown to predict venlafaxine treatment response.
Problematic digital media use
Pathophysiology
The pathophysiology of GAD is an active and ongoing area of research, often involving the intersection of genetics and neurological structures. GAD has been linked to changes in functional connectivity of the amygdala and its processing of fear and anxiety. Sensory information enters the amygdala through the nuclei of the basolateral complex (consisting of lateral, basal, and accessory basal nuclei). The basolateral complex processes the sensory-related fear memories and communicates information regarding threat importance to memory and sensory processing elsewhere in the brain, such as the medial prefrontal cortex and sensory cortices. Neurological structures traditionally appreciated for their roles in anxiety include the amygdala, insula and orbitofrontal cortex (OFC). It is broadly postulated that changes in one or more of these neurological structures are believed to allow greater amygdala response to emotional stimuli in individuals who have GAD as compared to individuals who do not have GAD.
Individuals with GAD have been suggested to exhibit greater activation of the amygdala and medial prefrontal cortex (mPFC) in response to stimuli than individuals without GAD. However, the exact relationship between the amygdala and the frontal cortex (e.g., the prefrontal cortex or the orbitofrontal cortex [OFC]) remains poorly understood, as some studies report increased or decreased activity in the frontal cortex in individuals with GAD. Consequently, because of the tenuous understanding of the frontal cortex as it relates to the amygdala in individuals who have GAD, it's an open question as to whether individuals who have GAD bear an amygdala that is more sensitive than an amygdala in an individual without GAD or whether frontal cortex hyperactivity is responsible for changes in amygdala responsiveness to various stimuli. Recent studies have attempted to identify specific regions of the frontal cortex (e.g., dorsomedial prefrontal cortex [dmPFC]) that may be more or less reactive in individuals who have GAD or specific networks that may be differentially implicated in individuals who have GAD. Other lines of study investigate whether activation patterns vary in individuals who have GAD at different ages with respect to individuals who do not have GAD at the same age (e.g., amygdala activation in adolescents with GAD).
Evolutionary explanations From an evolutionary perspective, generalized anxiety can be viewed as an overextension of the protective mechanisms that help organisms avoid danger. Cost–benefit analyses, sometimes referred to as the "smoke detector principle" propose that false alarms (unnecessary worry) are less costly than failing to detect real threats. As a result, having a relatively low threshold for perceiving danger may have historically conferred survival benefits. In individuals with GAD, however, this adaptive threshold appears to be set too low or activated too often, generating pervasive worry about routine events and relatively minor stressors.
Empirical work supports the idea that GAD involves heightened reactivity in brain regions associated with threat detection, including the amygdala. Researchers have also found links between GAD and elevated inflammation markers, suggesting a possible physiological correlate for the chronic anxiety seen in the disorder. Although anxiety's defensive functions may have been advantageous in unpredictable environments, modern contexts can render this vigilance maladaptive when it persists as near-constant worry and avoidance. This view places GAD at the extreme end of a continuum, where otherwise beneficial anxiety responses overshoot, leading to significant distress and functional impairment.
Diagnosis
DSM-5 criteria The diagnostic criteria for GAD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association, are paraphrased as follows:No major changes to GAD have occurred since publication of the Diagnostic and Statistical Manual of Mental Disorders (2004); minor changes include wording of diagnostic criteria.
ICD-10 criteria The 10th revision of the International Statistical Classification of Diseases (ICD-10) provides a different set of diagnostic criteria for GAD than the DSM-5 criteria described above. In particular, ICD-10 allows diagnosis of GAD as follows:
See ICD-10 F41.1 Note: For children different ICD-10 criteria may be applied for diagnosing GAD (see F93.80).
Treatment Traditional treatment modalities broadly fall into two categories: psychotherapeutic and pharmacological intervention. In addition to these two conventional therapeutic approaches, areas of active investigation include complementary and alternative medications (CAMs), brain stimulation, exercise, therapeutic massage, balneotherapy, and other interventions that have been proposed for further study. Treatment modalities can, and often are, used concurrently so that an individual may pursue psychotherapy and pharmacological therapy. Both cognitive behavioral therapy (CBT) and medications (e.g., SSRIs) have been shown to be effective in reducing anxiety. A combination of both CBT and medication is generally seen as the most desirable approach to treatment.
Psychotherapy